Retatrutide vs Wegovy: How They Compare

Wegovy is the brand name for semaglutide when it is prescribed for chronic weight management. Retatrutide is a separate, investigational triple-agonist molecule from Eli Lilly that is not yet approved. Both are once-weekly injections associated with weight loss, which is why people compare them. Here's a clear look at what is publicly known.

Important: Retatrutide is not FDA-approved and cannot be prescribed. Wegovy is approved. This is educational information, not medical advice.

Is Wegovy the same as retatrutide?

No. Wegovy is semaglutide, a GLP-1 receptor agonist (single-receptor) approved for weight management. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon, and it is still in clinical trials. They are different drugs from different companies (Novo Nordisk makes Wegovy; Eli Lilly is developing retatrutide) and are not interchangeable.

Side-by-side comparison

Retatrutide: the investigational triple agonist

Retatrutide activates three receptors with a single molecule. In its Phase 2 obesity trial (New England Journal of Medicine), the 12 mg weekly dose produced about 24.2% mean weight loss at 48 weeks, with a subset of top-dose participants exceeding 30% weight loss. It is dosed once weekly, has a roughly 6-day half-life, and is now in the Phase 3 TRIUMPH program. Despite the attention its early numbers attract, retatrutide is not approved and not available by prescription.

Wegovy: approved semaglutide for weight management

Wegovy is semaglutide approved for chronic weight management in eligible adults and adolescents, used alongside a reduced-calorie diet and increased physical activity. It is a once-weekly injection that providers titrate gradually toward a 2.4 mg weekly maintenance dose. In its obesity program semaglutide produced roughly 15% average weight loss, and it has established FDA labeling and outcome data.

Which leads to more weight loss?

Retatrutide's Phase 2 figures were numerically higher than Wegovy's obesity-trial figures, but the two were studied in separate trials with different designs, so this is not a valid head-to-head comparison. Retatrutide has not completed Phase 3, and its true efficacy and safety will only be established through those trials and any regulatory review. An approved medicine like Wegovy has a complete evidence base that an investigational drug does not.

Can I get retatrutide for weight loss instead of Wegovy?

No. Retatrutide is investigational and cannot be prescribed. Wegovy and other approved medicines can be, through a healthcare provider. Products marketed as "retatrutide" outside clinical trials are not FDA-approved and may carry real safety risks. Your provider can walk you through approved options.

Medical Disclaimer

This page is general educational information, not medical advice. Retatrutide is investigational and not FDA-approved. Trial figures are reported as published in the referenced studies and are not dosing recommendations. RetaPal is a private tracking and reminder app only. It does not recommend, calculate, or suggest doses. Always follow the dose and schedule given by your own prescriber, and consult your healthcare provider before starting, stopping, or changing any medication.

Once your provider has set your plan, RetaPal can log each weekly dose and count down to your next injection, private, offline, and never suggesting a dose itself.